Anbio Biotechnology (NNNN) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anbio Biotechnology is the larger company by market cap ($185.7 million vs $2.5 million), about 73.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | VRAX |
|---|---|---|
| Share price | $4.23 | $1.89 |
| Market cap | $185.66M | $2.54M |
| 1-day change | -8.44% | -5.03% |
| YTD return | -84.64% | — |
| 1-year return | -85.09% | — |
| P/E ratio (TTM) | 28.20 | — |
| EPS (TTM) | $0.15 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $21.75 |
| 52-week low | $4.20 | $1.81 |
| Distance from 52-week high | -90.54% | -91.31% |
| Average volume | 146.84K | 650.11K |
| Shares outstanding | 43.89M | 1.34M |
| Employees | 27 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 73.0 times larger than Virax Biolabs Group by market value ($185.66M vs $2.54M).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
NNNN vs VRAX FAQ
Which is bigger, Anbio Biotechnology or Virax Biolabs Group?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $185.66M compared with $2.54M for Virax Biolabs Group (VRAX).
Are Anbio Biotechnology and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.